Epigenetic regulation of microRNAs in cancer: shortening the distance from bench to bedside
| dc.contributor.author | Pajares Villandiego, María Josefa | |
| dc.contributor.author | Alemany Cosme, Ester | |
| dc.contributor.author | Goñi Irigoyen, Saioa | |
| dc.contributor.author | Bandrés Elizalde, Eva | |
| dc.contributor.author | Palanca Ballester, Cora | |
| dc.contributor.author | Sandoval, Juan | |
| dc.contributor.department | Ciencias de la Salud | es_ES |
| dc.contributor.department | Osasun Zientziak | eu |
| dc.date.accessioned | 2022-01-12T08:17:19Z | |
| dc.date.available | 2022-01-12T08:17:19Z | |
| dc.date.issued | 2021 | |
| dc.description.abstract | Cancer is a complex disease involving alterations of multiple processes, with both genetic and epigenetic features contributing as core factors to the disease. In recent years, it has become evident that non-coding RNAs (ncRNAs), an epigenetic factor, play a key role in the initiation and progression of cancer. MicroRNAs, the most studied non-coding RNAs subtype, are key controllers in a myriad of cellular processes, including proliferation, differentiation, and apoptosis. Furthermore, the expression of miRNAs is controlled, concomitantly, by other epigenetic factors, such as DNA methylation and histone modifications, resulting in aberrant patterns of expression upon the occurrence of cancer. In this sense, aberrant miRNA landscape evaluation has emerged as a promising strategy for cancer management. In this review, we have focused on the regulation (biogenesis, processing, and dysregulation) of miRNAs and their role as modulators of the epigenetic machinery. We have also highlighted their potential clinical value, such as validated diagnostic and prognostic biomarkers, and their relevant role as chromatin modifiers in cancer therapy. | en |
| dc.description.sponsorship | This study has been funded by Instituto de Salud Carlos III through the project 'PI19/00572' (Co-funded by European Regional Development Fund, 'A way to make Europe'). and INNVA1/2020/71 de la Línea 1 de Valorización y Transferencia a las empresas, de la Agencia Valenciana de la Innovación. | en |
| dc.format.extent | 23 p. | |
| dc.format.mimetype | application/pdf | en |
| dc.identifier.doi | 10.3390/ijms22147350 | |
| dc.identifier.issn | 1422-0067 | |
| dc.identifier.uri | https://academica-e.unavarra.es/handle/2454/41746 | |
| dc.language.iso | eng | en |
| dc.publisher | MDPI | en |
| dc.relation.ispartof | International Journal of Molecular Sciences, 22 (14), 7350 | en |
| dc.relation.publisherversion | https://doi.org/10.3390/ijms22147350 | |
| dc.rights | © 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license. | en |
| dc.rights.accessRights | info:eu-repo/semantics/openAccess | |
| dc.rights.uri | https://creativecommons.org/licenses/by/4.0/ | |
| dc.subject | Epigenetics | en |
| dc.subject | DNA methylation | en |
| dc.subject | MicroRNAs | en |
| dc.subject | Cancer | en |
| dc.subject | Biomarkers | en |
| dc.subject | Clinical applications | en |
| dc.title | Epigenetic regulation of microRNAs in cancer: shortening the distance from bench to bedside | en |
| dc.type | info:eu-repo/semantics/article | |
| dc.type.version | info:eu-repo/semantics/publishedVersion | |
| dspace.entity.type | Publication | |
| relation.isAuthorOfPublication | 601df8fd-4b6f-47c4-be5d-4b81d2c1cf64 | |
| relation.isAuthorOfPublication | 7945ddd5-cf8b-4927-bd7a-4ade2fb61f11 | |
| relation.isAuthorOfPublication | d2b52d9e-e5c2-428f-825e-91fcd49923f0 | |
| relation.isAuthorOfPublication.latestForDiscovery | 601df8fd-4b6f-47c4-be5d-4b81d2c1cf64 |